Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

Abstract Background Despite the advances of potent oral P2Y12 inhibitors, their onset of action is delayed, which might have a negative impact on clinical outcome in patients undergoing percutaneous coronary intervention (PCI). Trials conducted in the United States of America have identified cangrel...

Full description

Bibliographic Details
Main Authors: A. Selvarajah, A. H. Tavenier, W. L. Bor, V. Houben, S. Rasoul, E. Kaplan, K. Teeuwen, S. H. Hofma, E. Lipsic, G. Amoroso, M. A. H. van Leeuwen, J. M. ten Berg, A. W. J. van ‘t Hof, R. S. Hermanides
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cardiovascular Disorders
Subjects:
Cangrelor
P2Y12 inhibitors
Percutaneous coronary intervention
Platelet inhibition
Online Access:https://doi.org/10.1186/s12872-021-02093-4

Internet

https://doi.org/10.1186/s12872-021-02093-4

Similar Items